Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MaxCyte, Inc.
With
CTI Clinical Trial and Consulting Services
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be able to undergo peripheral blood leukapheresis; have successful placement of an intraperitoneal catheter
Be diagnosed with one of the following: metastatic or unresectable high grade serous adenocarcinoma involving the ovary, primary peritoneum, or fallopian tube with peritoneal involvement, not including mixed histologies, OR unresectable epithelioid or biphasic peritoneal mesothelioma
Be at least 4 weeks from previous anti-cancer therapy
Have a life expectancy of greater than 3 months.
You may not be if
Females who are pregnant, trying to become pregnant, or breastfeeding
Diagnosis of HIV or chronic active Hepatitis B or C
Symptomatic or uncontrolled brain metastases requiring current treatment
Impaired cardiac function or clinically significant cardiac disease
Lack of recovery of prior mild adverse events due to earlier therapies
Active infection
Another previous or current malignancy within the last 3 years, with exceptions
Concomitant chronic use of steroids or NSAIDs
Concomitant use of complementary or alternative medication or therapy
Autoimmune disease or inflammatory disease within previous 5 years
Clareo Health | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
